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Abstract
Background: Infection with H. pylori is important in the etiology of gastric cancer. Gastric cancer is infrequent in
Africa, despite high frequencies of H. pylori infection, referred to as the African enigma. Variation in environmental
and host factors influencing gastric cancer risk between different populations have been reported but little is
known about the biological differences between gastric cancers from different geographic locations. We aim to
study genomic instability patterns of gastric cancers obtained from patients from United Kingdom (UK) and South
Africa (SA), in an attempt to support the African enigma hypothesis at the biological level.
Methods: DNA was isolated from 67 gastric adenocarcinomas, 33 UK patients, 9 Caucasian SA patients and 25
native SA patients. Microsatellite instability and chromosomal instability were analyzed by PCR and microarray
comparative genomic hybridization, respectively. Data was analyzed by supervised univariate and multivariate
analyses as well as unsupervised hierarchical cluster analysis.
Results: Tumors from Caucasian and native SA patients showed significantly more microsatellite instable tumors
(p < 0.05). For the microsatellite stable tumors, geographical origin of the patients correlated with cluster
membership, derived from unsupervised hierarchical cluster analysis (p = 0.001). Several chromosomal alterations
showed significantly different frequencies in tumors from UK patients and native SA patients, but not between UK
and Caucasian SA patients and between native and Caucasian SA patients.
Conclusions: Gastric cancers from SA and UK patients show differences in genetic instability patterns, indicating
possible different biological mechanisms in patients from different geographical origin. This is of future clinical
relevance for stratification of gastric cancer therapy.
Background
Gastric cancer is the second most common cause of
cancer death worldwide, but incidence and mortality
rates show large variations across different countries.
Japan and China show the highest incidence rates of
gastric cancer of 80-115 cancers/100,000 population and
32-59 cancers/100,000 population respectively, while in
other Asian counties, such as India, Bangladesh, and
Thailand, the incidence rates are much lower (10.6, 1.3,
and 7.1 per 100,000 populations, respectively). Also
within Europe, incidence and mortality rates differ
between countries. Portugal has the highest incidence
rates (33.2/100,000) whereas other countries in Western
Europe show incidence rates of 19.4 per 100,000 popula-
tions. In the Netherlands it ranks fifth as a cause of cancer
death with incidence rates of 14.6/100,000. In Africa, gas-
tric cancer is infrequent, with incidence rates varying
between 6.9/100,000 in Northern Africa, 12.9/100,000 in
Eastern Africa, 11.9/100,000 in Southern Africa and
7.0/100,000 in Western Africa (Table 1) [1-3].
According to the Correa model, intestinal type gastric
cancers arise through a sequence of events, starting with
chronic active gastritis due to infection with Helicobac-
ter pylori (H. pylori). This chronic inflammatory process
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may lead to atrophy, intestinal metaplasia followed by
dysplasia and eventually may lead to invasive adenocar-
cinoma [4].
The mechanism by which H. pylori contributes to gas-
tric carcinogenesis is still largely unknown. However, we
do know that gastric cancer is the result of accumula-
tion of (epi)genetic changes. In gastric cancer, at least
two types of genetic instability play a role. Microsatellite
instability (MSI) occurs in cancers associated with
Lynch syndrome or hereditary non-polyposis colorectal
cancer (HNPCC), and in 10-15% of sporadic gastric can-
cers due to hMLH1 promoter hypermethylation [5,6].
However, the majority of gastric cancers show chromo-
somal instability, resulting in DNA copy number aberra-
tions that can be analyzed in detail by high resolution
array comparative genomic hybridization (array CGH).
In a previous study using chromosome based compara-
tive genomic hybridization (CGH), we were unable to
demonstrate that there are specific chromosomal altera-
tions which are associated with H. pylori infection [7].
Infection with H. pylori is important in the etiology of
gastric cancer, consequently high incidences of gastric
cancer are observed in areas with high prevalence of
H. pylori infection, like Asia. However, despite high fre-
quencies of H. pylori infection in Africa, gastric cancer
is infrequent in Africa, a phenomenon often referred to
as the ‘African enigma’ [8,9]. We hypothesize that
geographical differences in environmental factors, includ-
ing infection with H. pylori, and host factors are reflected
by different biological characteristics of the tumors from
those areas. Therefore, we compared MSI status and
DNA copy number profiles in gastric cancer patients
from United Kingdom (UK) and South Africa (SA).
Methods
Material
A total of 67 gastric adenocarcinomas were included in
this study. Of these, 33 gastric adenocarcinomas were
obtained from Leeds (Leeds, General Infirmary, UK) and
34 gastric adenocarcinomas were obtained from Pretoria
(Prinshof Campus, Pretoria, South Africa), of which 25
were obtained from native South African patients (native
SA) and 9 from Caucasian South African patients
(Caucasian SA), respectively. All tumors were randomly
selected after testing for proper DNA quality as pre-
viously described [10]. All gastric adenocarcinomas were
staged according to the TNM classification (5th edition)
for the grading and to the Laurén’s classification for
morphology [11]. The study was approved by the Insti-
tutional Review Board and was in accordance with local
medical ethical regulations.
DNA isolation procedure
DNA was isolated from formalin-fixed and paraffin
embedded gastric cancer material as described previously,
[12,13] using the QIAamp microkit (Qiagen, Hilden,
Germany). DNA concentrations were measured using a
Nanodrop ND-1000 spectrophotometer (Isogen, IJssel-
stein, The Netherlands) and DNA quality was assessed by
isothermal amplification [10]. Genomic DNA isolated
from peripheral blood obtained from eighteen healthy
females or males was pooled to use as normal reference.
Microsatellite instability (MSI) analysis
MSI analysis was performed using the MSI Analysis
System (MSI Multiplex System Version 1.1, Promega)
consisting of five nearly monomorphic mononucleotide
markers (BAT-25, BAT-26, NR-21, NR-24, MONO-27)
according to the manufacturer’s instructions. PCR pro-
ducts were separated by capillary electrophoresis using
an ABI 3130 DNA sequencer (Applied Biosystems,
Foster City, CA, USA), and analyzed using GeneScan
3100 (Applied Biosystems, Foster City, CA, USA). An
internal lane size standard was added to the PCR
samples for accurate sizing of alleles and to adjust for
run-to run variations. When all markers were stable, the
tumor was interpreted as microsatellite stable (MSS).
The tumor was interpreted as MSI-low (MSI-L) if one
marker was instable and MSI-high (MSI-H) if two or
more markers showed instability. MSI-L tumors were
included in the MSS category in further analysis. Due to
polymorphisms[14] in the South African population,
native South African tumors were classified as MSI
when three or more markers were instable.
Array CGH
Array CGH was performed as described before [12,15].
Briefly, 600 ng tumor and normal reference DNAs were
labeled by random priming (Bioprime DNA Labeling
System, Invitrogen, Breda, The Netherlands) and hybri-
dized onto a BAC array containing approximately 6000
clones, consisting of the Sanger BAC clone set with an
average resolution along the whole genome of 1.0 Mb,
the OncoBac set, containing approximately 600 clones
corresponding to 200 cancer-related genes, and selected
clones of interest obtained from the Children’s Hospital
Oakland Research Institute (CHORI) to fill gaps larger
Table 1 Incidence rates of gastric cancers per 100,000
populations
Incidence rates Incidence rates
Japan 80-115 Netherlands 14.6
China 32-59 Western Europe 19.4
India 10.6 Northern Africa 6.9
Bangladesh 1.3 Eastern Africa 12.9
Thailand 7.1 Southern Africa 11.9
Portugal 33.2 Western Africa 7.0
Buffart et al. BMC Medical Genomics 2011, 4:7
http://www.biomedcentral.com/1755-8794/4/7
Page 2 of 12
than 1 Mb on chromosome 6 and to have full coverage
contigs of regions on chromosome 8, 13 and 20. All
clones were printed in triplicate on Nexterion slides
(Schott Nexterion, Jena, Germany). Subsequent analysis
was performed according to the clone position from the
UCSC May 2004 freeze of the Human Genome Golden
Path http://genome.ucsc.edu.
Image acquisition and data analysis
Images of the arrays were acquired by scanning (Agilent
DNA Microarray scanner, Agilent Technologies, Palo
Alto, USA) and Bluefuse software version 3.4 (Blue-
Gnome, Cambridge, UK) was used for automatic feature
extraction. Spots were excluded when the quality flag
was below 1 or the confidence value was below 0.1.
Log2 tumor to normal ratio was calculated for each
clone and median block normalization was used to nor-
malize the data. Quality of array CGH profiles was mea-
sured by calculating a median absolute deviation value
of chromosome 2 (MAD2) [10]. Array CGH profiles
with MAD2 values >0.18 were excluded from further
analysis. For determining copy number gains and losses,
the R package CGH call was used [16]. Output of the
CGH call analysis was used for CGH region analysis to
compress the data, using a threshold for average error
rate of 0.001 [17]. Hierarchical cluster analysis was per-
formed using the WECCA program, with the parameter
total linkage [18].
Array data can be accessed using the Gene Expression
Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/,
under accession number GSE22789.
Statistical analysis
Significance of differences for categorical variables
between different categories was tested using a chi-
square test. One-way ANOVA with Bonferroni correc-
tion was used to calculate significant differences for
continuous variables between Caucasian SA, native SA,
and UK patients (SPSS 12.0.1 for Windows, SPSS Inc,
Chicago, IL, USA). P values less than 0.05 were consid-
ered to be significant.
Supervised analysis was performed using the non-para-
metric Mann-Whitney two-sample test (CGH test [19]).
Alterations in patterns between different tumor groups
were compared using a binomial differential proportion
test. The test procedure included a permutation-based
false discovery rate correction for multiple testing [20].
Two-sided p values less than 0.05 and false discovery
rates below 0.15 were considered to be significant.
Results
Clinicopathological data
The mean age of the UK gastric cancer patients was
73.3 years (range 51-96), mean age of the Caucasian SA
patients was 68.0 years (range 56-84) and the mean age
of the native SA patients was 56.5 years (range 29-79).
One-way ANOVA with Bonferroni correction yielded a
significant difference between the mean age of
the patients between native and Caucasian SA patients
(p = 0.03) and between native SA and UK patients (p <
0.001), but not between Caucasian SA and UK patients
(n.s).
There was no significant difference between patients
of different geographical location and gender, tumor
stage (T-category) and lymph node stage (N-category).
UK gastric cancers showed significantly more diffuse
type morphology compared to South African gastric
cancers (p = 0.002). Overview of patient and tumor
characteristics is given in Table 2.
Microsatellite instability (MSI) analysis
Two out of nine (22%) Caucasian SA gastric cancers, six
out of 25 (24%) native SA gastric cancers, and one out
of 33 (3%) UK gastric cancers showed MSI. All other
gastric cancers were MSS (Table 2). Pearson chi-square
yielded a significant difference between the three differ-
ent tumor groups and MSI status (p < 0.05).
Hierarchical cluster analysis
We analyzed DNA from all gastric cancers by genome-
wide array CGH analysis to unravel DNA copy number
changes in tumors from different geographical location.
MSI positive gastric cancers and gastric cancers with
array CGH profiles with a MAD2 value above 0.18 were
excluded for cluster analysis leaving 56 tumors (from
32 UK, 17 native SA and 7 Caucasian SA patients) for
further analysis.
Hierarchical cluster analysis yielded seven clusters
which were significantly correlated with gastric cancers
of different geographical origin (p < 0.001) (Figure 1).
Clusters 1, 2 and 7 obtained only gastric cancers from
UK patients. Clusters 3 and 4 comprised of gastric can-
cers from UK and native SA patients. Cluster 5 con-
tained only gastric cancers from SA patients, and cluster
6 contained a mixture of tumors of all three groups
(Table 2).
UK patients showed significantly more gastric adeno-
carcinomas of the diffuse type according to the Laurén
classification [11] compared to SA patients (p = 0.002).
We therefore repeated the cluster analysis including
only intestinal type gastric carcinomas. Cluster member-
ship of the remaining 12 tumors from UK patients and
12 and 7 tumors from native SA and Caucasian SA
patients, respectively, was again significantly correlated
to geographical origin of the patient (p < 0.001). More-
over, when analyzing only UK gastric cancers, hierarchi-
cal cluster analysis did not separate intestinal and
diffuse type gastric cancers, nor were any significant
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Table 2 Tumor and patient characteristics of the 67 tumors used for MSI and array CGH analysis
ID gender age Tumor type T N origin MSI status Cluster number Cluster order % events % gains % losses
1 F 62 intestinal T2 N1 Cauc SA MSS 5 34 3.2 3.2 0
2 M 73 intestinal T2 N2 Cauc SA MSS 5 28 16.9 13.4 3.4
3 F 59 intestinal T2 N1 Cauc SA MSS 5 26 26.5 15.1 11.4
4 F 74 intestinal T2 N1 Cauc SA MSS 5 27 15.7 9.3 6.5
5 M 56 intestinal T3 N1 Cauc SA MSI - - 15.6 10.3 5.3
6 M 57 intestinal T2 N1 Cauc SA MSS 6 48 3.4 2.4 1.0
7 F 84 intestinal T1 N0 Cauc SA MSS 6 43 10.9 7.9 3.1
8 F 79 intestinal T3 N0 Cauc SA MSI - - 17.6 16.8 0.8
9 M 68 intestinal T3 N2 Cauc SA MSS 5 25 32.1 24.3 7.7
10 M 65 intestinal T2 N0 native SA MSI - - 1.7 1.7 0
11 M 57 intestinal T1 N0 native SA MSI - - 0 0 0
12 F 29 intestinal T4 N0 native SA MSS 6 37 28.3 26.2 2.1
13 F 59 intestinal T3 N1 native SA MSS 6 42 10.6 5.3 5.3
14 M 66 intestinal T2 N1 native SA MSS 5 31 6.4 6.4 0
15 M 46 intestinal T3 N2 native SA MSS 5 35 3.2 3.2 0
16 F - diffuse T4 N2 native SA MSS 6 44 13.2 12.4 0.7
17 M 51 intestinal T3 N1 native SA MSS 5 32 6.1 6.1 0
18 F 49 intestinal T3 N1 native SA MSS 4 20 29.1 18.2 10.9
19 M 56 intestinal T3 N1 native SA MSS 4 19 26.0 10.3 15.7
20 M 48 intestinal T3 N2 native SA MSS 5 36 5.4 5.4 0
21 M 65 mixed T3 N1 native SA MSI - - 18.2 16.3 1.9
22 M 60 intestinal T2 - native SA MSS 6 41 14.0 11.3 2.7
23 F 63 intestinal - - native SA MSS 6 38 17.1 10.7 6.4
24 F 54 papillary T2 N0 native SA MSS 3 14 44.8 20.6 24.2
25 M 67 intestinal T3 N1 native SA MSS - - - - -
26 M 31 intestinal T3 N1 native SA MSS 5 24 41.1 28.4 12.7
27 M 43 intestinal T3 N1 native SA MSI - - 9.9 9.9 0
28 F 71 intestinal T3 - native SA MSS 5 33 3.7 2.7 1.0
29 F 77 intestinal T3 N1 native SA MSS 5 30 12.7 7.1 5.5
30 M 57 intestinal T2 N0 native SA MSS - - - - -
31 M 79 intestinal T3 N2 native SA MSI - - 2.5 2.5 0
32 M 57 intestinal T4 N0 native SA MSI - - 17.8 16.8 1.0
33 M 56 mixed T3 N1 native SA MSS 4 17 42.2 21.3 20.9
34 F 49 mixed T3 N3 native SA MSS 5 29 22.3 19.2 3.2
35 F 82 diffuse T1 N0 UK MSS 6 46 11.2 10.3 1.0
36 M 81 diffuse T3 N2 UK MSS 4 22 15.7 7.2 8.5
37 M 71 diffuse T2 N1 UK MSS 7 53 18.4 14.7 3.7
38 M 73 intestinal T2 N0 UK MSS 2 11 26.0 17.2 8.8
39 F 65 diffuse T2 N3 UK MSS 6 45 15.0 12.0 3.1
40 F 58 diffuse T3 N3 UK MSS 1 6 25.7 13.7 12.0
41 F 51 diffuse T3 N3 UK MSS 1 7 22.4 16.5 6.0
42 M 91 intestinal T1 N0 UK MSS 7 56 49.2 27.6 21.6
43 M 71 diffuse T3 N2 UK MSS 7 49 40.6 19.8 20.8
44 M 73 intestinal T2 N1 UK MSS 1 5 21.0 8.2 12.9
45 M 64 diffuse T2 N0 UK MSS 7 50 14.9 10.3 4.6
46 F 71 intestinal T1 N0 UK MSS 1 4 40.8 13.4 27.4
47 F 60 intestinal T4 N1 UK MSS 3 16 30.1 15.6 14.5
48 F 96 diffuse T3 N0 UK MSS 2 12 41.0 25.0 16.0
49 M 91 mixed T3 N0 UK MSS 6 40 16.0 11.4 4.6
50 M 81 diffuse T2 N0 UK MSS 2 10 37.7 17.2 20.4
51 F 83 intestinal T2 N0 UK MSS 7 51 14.5 10.5 4.0
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differences observed between these two morphological
tumor types with supervised analysis using CGH test.
Cluster membership was independent of gender, tumor
stage, lymph node stage and of age of the patients (cate-
gorized as < 50 years of age versus ≥ 50 years of age).
DNA copy number changes
We first compared the number of events, which was
defined as percentage of clones showing a gain or loss.
Gastric cancers from UK patients showed a higher num-
ber of events (27% (range 2-49%)) compared to cancers
from Caucasian SA (16% (range 3-32%)) and native SA
patients (16% (range 0-45%)) (p = 0.005). Cancers from
UK, Causasian SA and native SA patients showed 15%
(range 2-28%), 11% (range 2-24%) and 11% (range 0-
28%) of gained clones respectively, and 12% (range 0-
27%), 4% (range 0-11%) and 5% (0-24%) clones showing
a loss, respectively. A significant difference in the per-
centage of clones showing a loss was observed between
UK patients and Caucasian SA patients (p = 0.002) and
between UK patients and native SA patients (p = 0.02).
Also, when looking only at microsatellite stable gastric
cancers UK patients showed a higher number of events
(27% (range 2-49%)) compared to microsatellite stable
cancers from Caucasian SA and native SA patients (16%
(range 3-32%) and 19% (range 3-45%), respectively; p =
0.04). Microsatellite stable cancers from UK, Caucasian
SA and native SA patients showed 15% (range 2-28%),
12% (range 2-24%) and 13% (range 3-28%) of gained
clones, respectively. There was again a significant differ-
ence in percentages of clones showing a loss between
cancers from UK and Caucasian SA patients (12%
Figure 1 Cluster analysis of 56 gastric adenocarcinomas of
which 32, 17 and 7 were obtained from UK, native SA and
Caucasian SA patients, respectively. Hierarchical cluster analysis
yielded 7 clusters significantly correlated with geographical origin of
the tumors (p < 0.001). Columns represent the different tumors and
rows represent the different chromosomal regions, with
chromosome 1 at the bottom and chromosome 22 at the top of
the heatmap. DNA copy number gains and losses are indicated in
green and red, respectively. The yellow and blue bar next to the
cluster represents the chromosome separation.
Table 2 Tumor and patient characteristics of the 67 tumors used for MSI and array CGH analysis (Continued)
52 F 82 intestinal T3 N1 UK MSS 6 47 2.2 2.2 0
53 F 77 intestinal T3 N1 UK MSS 6 39 19.5 11.1 8.5
54 M 74 mixed T2 N1 UK MSS 2 8 44.8 22.4 22.3
55 F 59 diffuse T3 N1 UK MSS 3 15 26.4 18.1 8.2
56 M 77 mixed T3 N2 UK MSS 1 3 24.1 13.7 10.3
57 M 75 intestinal T2 N0 UK MSS 2 9 36.9 18.2 18.7
58 M 64 diffuse T3 N3 UK MSS 2 13 35.3 20.2 15.1
59 M 71 intestinal T3 N1 UK MSS 1 2 31.0 11.7 19.3
60 F 74 diffuse T3 N2 UK MSS 4 23 23.2 14.7 8.4
61 M 81 intestinal T2 N0 UK MSI - - 10.7 8.7 2.0
62 F 74 mixed T3 N2 UK MSS 4 18 30.4 17.9 12.5
63 M 67 mixed T3 N1 UK MSS 7 52 12.3 6.4 5.9
64 M 73 intestinal T3 N1 UK MSS 4 21 15.2 7.3 7.9
65 F 66 mixed T3 N2 UK MSS 7 55 34.3 18.7 15.6
66 M 82 intestinal T1 N1 UK MSS 7 54 46.7 27.4 19.3
67 F 62 mixed T3 N0 UK MSS 1 1 44.0 20.7 23.3
Percentages of events, gains and losses are given for all tumors of sufficient array CGH quality. Cluster number and order are listed for the 56 cases included in
the cluster analysis.
F: female, M: male, T: T-stage, N: N-stage MSS: microsatellite stable, MSI: microsatellite instable, Cauc SA: Caucasian South African patients, native SA: native South
African patients, UK: patients from United Kingdom, -: unknown.
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Table 3 Detailed overview of frequent DNA copy number aberrations (>30%) of tumors from UK patients
chromosomal aberrations flanking clones position (bp) segment size
gains losses start end start end (Mb)
1p36.33-p36.21 RP11-206L10 RP4-636F13 672780 12417597 11.74
1p31.1 RP5-944F13 RP11-246O4 69815162 83112098 13.30
1p21.3-p13.3 RP11-146P11 RP5-1077K16 95695632 107389118 11.69
1q21.2-q23.1 RP4-790G17 RP11-214H6 146971278 153444622 6.47
1q31.1-q31.3 RP11-134C1 RP11-75C23 184717073 194242465 9.53
1q32.1-q32.2 RP11-150l7 RP11-564A8 197877387 203602276 5.72
3p26.3 RP11-385A18 RP11-129K1 46140 2377366 2.33
3p25.1-p24.1 RP11-255O19 RP11-99M10 15780361 30799547 15.02
3p14.2 RP11-170K19 RP11-114P15 59701329 62639806 2.94
3p12.3-p11.2 RP11-103P13 RP11-91M15 75146113 96627928 21.48
4p16.1-q35.2 RP11-61G19 CTC-963K6 10275012 191158370 180.88
5p15.33 RP11-811I15 CTD-2265D9 70262 2671745 2.60
5q11.1-q23.3 RP11-269M20 RP11-114H7 49913067 130460728 80.55
6p21.32-p21.1 RP11-79I1 RP11-121G20 33123932 44385866 11.26
7p22.3-p22.1 RP11-713A20 RP11-161C7 106471 6396697 6.29
7p11.2 RP11-449G3 RP11-34J24 54413814 55403627 0.99
7q22.1 RP11-10D8 RP11-163M5 98067793 101528379 3.46
7q36.1 RP11-89P11 RP11-43l19 147485335 151131938 3.65
7q36.3 RP11-58F7 RP11-120H14 157072238 158524109 1.45
8q24.12-q24.3 RP11-22A24 RP5-1109M23 120711365 146238749 25.53
9p24.3-p21.1 RP11-48M17 RP11-141J7 2136329 32469400 30.33
9q33.3-q34.3 RP11-205K6 RP11-424E7 126296075 138363252 12.07
10p15.3 RP11-631M21 RP11-74N14 50000 1789100 1.74
10p15.2 RP11-195B3 3293007 3338470 0.05
10q22.1 RP11-91A1 RP11-28E3 72033907 73573433 1.54
11p15.5-p15.4 CTC-908H22 RP11-304P12 178227 3140168 2.96
11q12.2-q13.5 RP11-286N22 RP11-30J7 60851860 76232373 15.38
12q21.2-q22 RP1-97G4 RP11-2K12 76228586 91346299 15.12
13q11-q12.11 RP11-94A1 RP11-61K9 18360157 19386914 1.03
13q21.2-q21.33 RP11-310K10 RP11-451E2A 60721181 71574154 10.85
13q32.3 RP11-19J14 RP11-113F15 97851594 99328275 1.48
13q33.3-q34 RP11-61I17 RP11-569D9 108847725 114103243 5.26
14q12 RP11-330O19 RP11-109D12 25538832 26345513 0.81
14q21.1-q21.3 RP11-88D14 RP11-94K16 36949212 48298851 11.35
14q31.1-q31.3 RP11-46l17 RP11-88N20 78630860 86772926 8.14
14q32.31-q32.33 RP11-367F11 RP11-815P21 101467534 105159201 3.69
15q14 RP11-294M6 RP11-79A5 33841939 35953471 2.11
16p13.3 CTD-2148K8 RP11-89M4 87754 4697230 4.61
16p13.2-p13.11 RP11-475D10 RP11-489O1 8598165 15572359 6.97
16p12.1-p11.2 RP11-142A12 RP11-18H23 26595069 31443695 4.85
16q21-q22.1 RP11-52B24 RP11-394B2 63708677 69365102 5.66
16q23.3-q24.3 RP11-483P21 RP11-566K11 82361609 88613383 6.25
17p13.3-p13.1 RP11-411G7 RP11-89A15 427024 8365794 7.94
17p11.2 RP11-524F11 RP1-162E17 17343389 19251691 1.91
17q11.2-q21.31 RP11-138P22 RP11-374N3 23133763 41096064 17.96
17q21.32-q21.33 RP11-234J24 RP11-506D12 42655422 46333070 3.68
17q22-q23.2 RP11-143M4 RP11-139B3 47607556 51363278 3.76
17q24.3-q25.3 RP11-65C22 RP11-258N23 68165339 78308832 10.14
18q11.2-q23 RP11-5G23 RP11-396D4 21431314 71337306 49.91
19p13.3-q13.43 RP11-110A24 GS1-1129C9 134914 63771717 63.64
20p13-q13.33 RP11-530N10 CTB-81F12 9943 62393015 62.38
21q11.2-q22.11 RP11-72P4 RP11-41N19 13857799 30673984 16.82
22q11.1-q11.21 RP11-81H21 RP11-586I18 14754982 18976359 4.22
22q12.3-q13.33 RP11-90I17 CTB-99K24 35686144 49397088 13.71
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(range 0-27%) and 4% (range 0-11%), respectively; p =
0.04) and between cancers from UK and native SA
patients (12% (range 0-27%) and 7% (range 0-24%)
respectively; p = 0.04).
An overview of frequently altered (>30%) chromosomal
regions with gains and losses per tumor group is given in
Tables 3, 4 and 5. Most frequently altered (>30%) chro-
mosomal regions observed in the UK tumors were gains
on chromosomes 1p, 1q, 5p, 6p, 7p, 7q, 8q, 9q, 10p, 10q,
11p, 11q, 13q, 14q, 16p, 16q, 17p, 17q, 19p, 19q, 20p,
20q, 21q and 22q and losses on chromosomes 1p, 1q, 3p,
4p, 4q, 5q, 9p, 12q, 13q, 14q, 15q, 17q, 18q and 21q
(Table 3). Most frequent DNA copy number aberrations
in the native SA patients were gains on the chromosomal
regions 7p, 7q, 8q, 9q, 17q, 19p, 19q, 20p and 20q, and
losses on 3p and 4q (Table 4). Most frequently altered
chromosomal regions in Caucasian SA patients were
gains on 3q, 5p, 7p, 7q, 8p, 8q, 9q, 11q, 16p, 17q, 19p,
19q, 20p and 20q and losses on 3p, 4q and 9p (Table 5).
A summary of frequencies of gains and losses of all gas-
tric cancers per tumor group is presented in Figures 2
(UK), 3 (native SA) and 4 (Caucasian SA).
Supervised analysis
To identify biological differences between gastric can-
cers from different geographical origin, native SA
Table 4 Detailed overview of frequent DNA copy number aberrations (>30%) of tumors from native SA patients
chromosomal aberrations flanking clones position (bp) segment size
gains losses start end start end (Mb)
3p14.2 RP11-734E15 RP11-137N22 59105371 61252524 2.15
4q35.2 RP11-354H17 CTC-963K6 190095484 191158370 1.06
7p22.3-p11.2 RP11-713A20 RP11-80l24 106471 55784518 55.68
7q22.1 RP11-10D8 RP11-163M5 98067793 101528379 3.46
8q24.3 RP11-472K18 RP5-1109M23 144481535 146238749 1.76
9q33.3-q34.3 RP11-91G7 RP11-424E7 124316484 138363252 14.05
17q12-q21.31 RP11-893G17 RP11-392O1 31506328 39091575 7.59
17q21.32-q21.33 RP1-62O9 RP11-506D12 44647598 46333070 1.69
17q23.2-q25.3 RP11-579A4 RP11-258N23 54149948 78451750 24.30
19p13.3 RP11-110A24 CTC-1482H14 134914 5154803 5.02
19p13.2-p13.11 RP11-197O4 RP11-88I12 10248852 19023254 8.77
19q12-q13.34 CTC-1459F4 GS1-1129C9 32889410 63771717 30.88
20p13-q13.33 RP11-530N10 CTB-81F12 9943 62393015 62.38
Table 5 Detailed overview of frequent DNA copy number aberrations (>30%) of tumors from Caucasian SA patients
chromosomal aberrations flanking clones position (bp) segment size
gains losses start end start end (Mb)
3p14.2 RP11-48E21 RP11-641C17 60380670 60705094 0.32
3q26.2-q26.31 RP11-669J9 RP11-44A1 172392313 173855790 1.46
4q32.1-q35.2 RP11-192D11 CTC-963K6 159886665 191158370 31.27
5p13.1-p12 RP11-17J3 RP11-55O15 40113135 44396362 4.28
7p22.3-p21.3 RP11-713A20 RP11-505D17 106471 7932634 7.83
7q22.1 RP4-550A13 RP11-333G13 98512376 101153193 2.64
8p23.1 RP11-241P12 RP11-589N15 9788949 11803111 2.01
8q22.1-q22.3 RP11-664H21 RP11-132E3 98618965 105402542 6.78
8q24.21 RP11-28I2 RP11-1142f3 127563658 129620230 2.06
9p24.1-p23 RP11-165O14 RP11-91E3 5873408 9689968 3.82
9q33.3-q34.3 RP11-62A6 RP11-424E7 124479347 138363252 13.88
11q13.3-q13.5 RP11-554A11 RP11-98G24 68509550 77008323 8.50
16p11.2 RP11-110P16 RP11-388M20 28675396 31163676 2.49
17q12-q21.1 RP5-986F12 RP11-94L15 33099924 35227135 2.13
17q25.1-q25.3 RP11-41E12 RP11-258N23 68729134 78451750 9.72
19p13.3-p13.11 RP11-110A24 RP11-88I12 134914 19023254 18.89
19q13.11-q13.43 CTC-1325L16 GS1-1129C9 37623641 63771717 26.15
20p13-q13.33 RP11-48M7 CTB-81F12 3728265 62393015 58.66
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tumors were compared with UK tumors using CGH
test. Only MSS tumors were included in the supervised
analysis. In total, 133 regions, located on different chro-
mosomes, were significantly different (p < 0.05 and
fdr≤0.15) between these two patient groups. An over-
view of the significant chromosomal regions, including
the fdr rates, is given in Table 6. No significant differ-
ences were found between gastric cancers from UK and
Caucasian SA patients or between gastric cancers from
native and Caucasian SA patients.
Discussion
One of the main risk factors contributing to gastric can-
cer is infection with H. pylori, which causes a chronic
active gastritis [4,21]. In South Africa, gastric cancer is
infrequent, while the prevalence of H. pylori infection is
very high. Although differences in genotypes of H. pylori
exist in different geographic areas, this African enigma
can not only be explained by differences in virulent
strains of H. pylori [22-24]. High prevalence of vacA s1b
strain is observed in South Africa as well as in Brazil
and Portugal, countries with high incidences of gastric
cancer, [25-27] and frequencies of CagA antibodies were
similar between patients with gastric neoplasia com-
pared to healthy controls [28]. The prevalence of the
different virulent strains in the present study is
unknown. Since H. pylori is thought to play a major role
in the initiation phase of gastric cancer development
and most often already disappeared at time of gastric
cancer diagnosis, it is impossible to accurately retrieve
this information.
Besides the virulence of the infecting H. pylori strain,
other factors influence gastric cancer risk, including
environmental factors such as diet and socioeconomic
status, and host factors, such as polymorphisms, which
are involved in the inflammatory response to the infec-
tion [29,30]. Knowing that the prevalence of H. pylori
infection and incidences of gastric cancer are different
in South Africa and Western Europe, we aimed to study
if this would reflect in different patterns of gastric
carcinogenesis.
The concept of the African enigma has been chal-
lenged since it has been suggested that the enigma
could be explained due to lack of infrastructure and
access to hospitals and care in African countries result-
ing in incomplete reporting of gastric cancer. However
the incidence of gastric cancer would have been so dra-
matically underestimated that it has been stated that
under-reporting by itself could not explain the lower
frequencies of gastric cancer in African countries [31].
Also, when using the proportional frequency of gastric
cancer compared to other cancer types in Africa, gastric
cancer incidence remains very low [8]. Another criticism
on the African enigma has been the high prevalence of
Figure 2 Frequencies of gains and losses throughout the
genome in all gastric adenocarcinomas from UK patients.
Clones are sorted by position per chromosome (1-22). Vertical lines
indicate transition between chromosomes; dashed vertical lines
indicate centromere position.
Figure 3 Frequencies of gains and losses throughout the
genome in all gastric adenocarcinomas from native SA
patients. Clones are sorted by position per chromosome (1-22).
Vertical lines indicate transition between chromosomes; dashed
vertical lines indicate centromere position.
Figure 4 Frequencies of gains and losses throughout the
genome in all gastric adenocarcinomas from Caucasian SA
patients. Clones are sorted by position per chromosome (1-22).
Vertical lines indicate transition between chromosomes; dashed
vertical lines indicate centromere position.
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Table 6 Detailed overview of the supervised analysis using CGH test
cytoband region start (bp) region end (bp) p-value fdr cytoband region start (bp) region end (bp) p-value fdr
1p36.33 672780 1359795 0.04 0.15 11p14.2-p14.1 27033269 27371257 0.05 0.15
1p36.32-p36.31 3386389 6294064 0.03 0.12 11q13.3 68509550 69323966 0.04 0.14
1p36.21-p36.13 12798944 15683816 0.03 0.12 11q13.3-q13.4 69314721 70472869 0.04 0.14
1p31.2 67178936 69303906 0.04 0.14 11q22.1-q22.2 98930611 101405228 0.03 0.12
1p31.1 69815162 76679895 0.01 0.06 11q22.2-q22.3 102010610 102424014 0.03 0.12
1p31.1 77428804 77820126 <0.01 0.04 12q21.2 76570565 78724263 0.04 0.14
1p21.2-p21.1 101684496 104502748 0.03 0.12 13q21.31-q21.33 61335626 69275204 0.04 0.14
1q31.1-q31.2 184717073 188976520 0.01 0.09 14q21.1 39694531 42171623 0.02 0.10
1q31.2-q31.3 189822405 193082884 0.02 0.10 14q21.2 42965408 44043547 0.01 0.09
1q31.3 193336091 194242465 0.01 0.08 14q21.2-q21.3 45258184 48298851 0.03 0.12
1q31.3 195068870 195629725 0.03 0.12 15q14 33841939 35953471 0.04 0.14
3p26.3 46140 2377366 <0.01 0.03 15q22.2 57373165 61214280 0.02 0.09
3p24.3 17181327 18148477 <0.01 0.03 15q23 65816865 68768615 0.02 0.09
3p24.3 19033520 21742232 <0.01 0.03 15q23-q24.2 69188639 73645336 0.05 0.15
3p24.3-p24.1 22747912 27531283 0.02 0.10 15q24.2-q25.2 74334873 81024206 0.03 0.12
3p21.31 46545403 47371983 0.05 0.15 16p13.2-p13.12 8777494 12522798 0.05 0.15
3p21.31 47384745 50114898 0.04 0.14 16p11.2 28675396 31163676 <0.01 0.04
3p21.31-p21.2 50533656 51418837 0.01 0.09 16q24.1 82993991 83622386 0.05 0.15
3p21.31-p21.2 51390596 52007218 0.02 0.09 16q24.1 84123856 84922042 0.02 0.09
3p21.1 52658450 53621497 0.01 0.09 16q24.2-q24.3 86986672 87452904 0.03 0.12
3p12.3 76450939 79097142 0.02 0.09 16q24.3 87848795 88465228 0.02 0.09
3p12.3-p12.2 79197544 82066233 <0.01 0.04 16q24.3 88398231 88613383 0.01 0.07
3p12.2-p12.1 82657794 84801874 <0.01 0.03 17p13.3 427024 1071560 <0.01 0.03
3p12.1-p11.2 85234579 87730259 <0.01 0.03 17p13.3-p13.2 2026966 4169913 0.04 0.14
3p11.1 88915283 89771786 <0.01 0.04 17p13.2 4810523 5166678 0.01 0.09
3q11.2 95569618 96250439 0.01 0.05 17p13.1 6780962 7477414 <0.01 0.03
3q25.1-q25.33 151508469 161536133 0.03 0.12 17p13.1 7436435 7682367 <0.01 0.03
3q25.33-q26.1 162044657 164516640 0.03 0.12 17p11.2 17343389 19251691 0.04 0.14
3q26.1 165289729 167697600 0.05 0.15 17q11.2 23133763 28423820 0.02 0.09
3q26.31-q26.32 174848631 180449332 0.05 0.15 17q11.2-q12 28664889 29147086 0.02 0.09
4p15.32-p14 17799729 36260048 0.02 0.11 17q25.1 69709369 71238958 0.01 0.09
4p14 36998587 37497326 0.01 0.09 17q25.1-q25.3 71406319 77588058 0.03 0.12
4p14 37851044 38103870 0.02 0.11 18q11.2 21431314 21774952 0.01 0.05
4p14-p12 38087293 46781512 0.01 0.09 18q11.2 22104619 22931012 <0.01 0.04
4q12 58332155 59148507 0.04 0.14 18q12.1 23970882 24526449 0.02 0.10
4q12-q13.1 59679465 62653308 0.02 0.10 18q12.1 25034674 26878315 0.01 0.08
4q13.3 74322497 76429795 0.03 0.12 18q12.1 27447009 28415095 0.01 0.09
4q13.3-q21.21 76495364 79353372 0.02 0.09 18q12.1 29409483 30219417 0.01 0.09
4q21.21 79222718 80683287 0.03 0.12 18q12.1-q12.2 30773824 31588529 0.01 0.06
4q33-q34.3 172094999 178721484 0.02 0.10 18q22.1 60340433 61310295 0.03 0.12
4q34.3 178969859 179599683 0.01 0.09 18q22.1 61623805 62645202 0.03 0.12
4q34.3 180819690 183096645 0.02 0.10 18q22.1-q22.3 63092764 68041625 0.03 0.12
4q35.1 184503994 186178296 0.03 0.12 19p13.3 134914 913289 0.01 0.08
5q11.2 50971745 52055659 0.04 0.14 19p13.3 902641 5009969 <0.01 0.04
5q11.2 52909242 56437163 0.03 0.12 19p13.3 5663923 6519297 <0.01 0.01
5q11.2-q12.1 56921490 58947885 0.02 0.09 19p13.3-p13.2 6523443 9826740 <0.01 <0.01
5q14.3 82802677 86118543 0.05 0.15 19p13.2-p13.12 10248852 15116365 <0.01 0.03
5q23.2 122463056 123527915 0.05 0.15 19p13.12-p13.11 15415833 17777501 <0.01 0.01
7p22.1-p21.3 6983150 7932634 <0.01 0.02 19p13.11 18202507 19023254 <0.01 0.03
7p21.3-p21.2 9256088 14085902 <0.01 <0.01 19p12 19877150 21504328 0.01 0.05
7p21.2-p21.1 14342152 19957111 <0.01 0.01 19p12 22133662 22949959 0.01 0.05
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HIV infection. A relatively large part of the African
population would die of HIV before the age in which
gastric cancer becomes more frequent. However, the
low gastric cancer incidence in Africa was described
before the HIV epidemic.
South African patients showed significantly more
microsatellite instable gastric cancers compared to Wes-
tern European patients. Also at the level of chromoso-
mal instability clear differences were found, reflected by
a significant correlation between cluster membership
and geographical tumor origin, i.e. UK, native SA and
Caucasian SA. Microsatellite instable gastric cancers are
described to have fewer chromosomal aberrations com-
pared to microsatellite stable gastric cancers [32,33]. To
rule out that tumors from South African patients cluster
together by hierarchical cluster analysis due to the fact
that these tumors show higher frequencies of microsa-
tellite instability, only microsatellite stable gastric can-
cers were included in the hierarchical cluster analysis.
Not much has been reported about microsatellite sta-
tus in gastric cancers from African patients. One study
reported infrequent microsatellite instable gastric can-
cers in South African patients[34] which is in contrast
with our findings which show a higher frequency of
microsatellite instability in gastric cancers from SA
patients compared to UK patients. Based on the present
data, MSI does play an important role in gastric carcino-
genesis in South Africa.
Several chromosomal aberrations are common in the
three different tumor groups analyzed, including gains
of chromosomes 7, 8q, 9q, 17q, 19 and 20 and losses of
3p and 4q, while other chromosomal changes are speci-
fic for each tumor group. In addition, gastric cancers
from UK patients showed a significantly higher number
of clones showing a loss compared to gastric cancers
form South African patients. These results indicate dif-
ferent patterns of chromosomal instabilities in gastric
cancers correlating to geographical origin of the patient.
The chromosomal aberrations of the UK tumors are
comparable to other array CGH studies analyzing Wes-
tern European tumors [12,35-37]. To the best of our
knowledge, this is the first array CGH study on gastric
cancers from South African patients. Since several chro-
mosomal regions are significantly different between gas-
tric cancers from different geographical origin, and each
region comprises multiple genes, further studies are
needed to pinpoint candidate genes contributing to the
differences in genomic profiles.
The higher frequency of diffuse gastric cancers from
UK patients compared to the SA patients in the present
study could be considered as a confounding factor.
Contradicting results have been published either
describing different or similar patterns of DNA copy
number aberrations between intestinal and diffuse type
gastric cancers [7,33,37-39]. In the context of the pre-
sent study we believe that the differences in DNA copy
number aberrations between UK and SA gastric cancers
are independent of the histological tumor type. When
repeating the cluster analysis with intestinal type carci-
nomas only, cluster membership again was significantly
correlated with geographical origin of the tumors. Also
supervised data analysis, i.e. testing copy number status
of all genomic loci, did not reveal any significant differ-
ences in DNA copy number changes between intestinal
and diffuse gastric cancers from UK patients. Further-
more, hierarchical cluster analysis including UK gastric
Table 6 Detailed overview of the supervised analysis using CGH test (Continued)
7q22.1 98651132 100929260 <0.01 0.03 19q12 33315121 33507712 0.02 0.10
8q24.21 130562467 131126185 0.05 0.15 19q12 34159370 34664148 0.02 0.11
8q24.22 131641447 133561490 0.01 0.09 19q12 34960906 35766560 0.02 0.11
8q24.22 134537164 136154996 0.02 0.11 19q12-q13.11 36958851 37518517 0.05 0.15
8q24.22-q24.23 136472354 138543270 0.04 0.14 19q13.12-q13.13 40883472 43004503 0.03 0.13
8q24.3 141395868 142790557 0.01 0.05 19q13.2-q13.32 46498596 50725496 0.03 0.12
8q24.3 144790054 145357620 0.01 0.09 19q13.32-q13.33 52665374 54718281 0.03 0.12
8q24.3 145585590 145953950 0.02 0.11 19q13.33-q13.43 55461670 63771717 <0.01 0.01
8q24.3 145893230 146238749 0.04 0.14 21q11.2-q21.1 13857799 18774434 <0.01 0.03
9p24.1-p23 8398601 9689968 0.04 0.14 21q21.1 20982315 21411332 <0.01 0.03
9p23 9684353 10554235 0.04 0.14 21q21.1-q21.2 22151920 22943367 <0.01 0.03
10q22.1 70824040 71674097 0.03 0.12 21q21.2 23491399 25568510 <0.01 0.01
10q22.1 72033907 73573433 0.02 0.09 21q21.3 26174732 26923374 0.02 0.09
10q26.3 135110821 135301208 0.03 0.12 21q21.3-q22.11 28596969 30855176 0.03 0.12
11p15.5 178227 626401 0.01 0.05 22q13.33 48473404 49397088 0.04 0.15
11p15.5 1299306 1785278 <0.01 0.03
In total, 133 regions were significantly different (p < 0.05 and fdr≤0.15) between UK and native SA tumors. The chromosomal regions, including the start and end
positions, and the fdr rates are listed.
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cancers only did not separate intestinal and diffuse type
gastric cancers. We therefore do not believe our findings
to be influenced by distribution of histological types in
this series. Question remains why diffuse type gastric
cancers were more frequently observed in gastric can-
cers from UK patients compared to SA patients. Besides
being a confounding factor, we can hypothesize that
mutation of E-cadherin (CDH1), or other mechanisms
disrupting the CDH1 gene function such as epigenetic
mechanisms or miRNAs, playing an important role in
diffuse type gastric cancer, might play a minor role in
SA gastric cancer patients due to different pathways of
carcinogenesis, as shown in the present study by differ-
ences in patterns of DNA copy number aberrations.
Also, the prevalence of H. pylori infection is very high
in South Africa, and H. pylori infection mainly plays a
role in intestinal type gastric cancers. This could also
explain the higher number of intestinal type gastric can-
cers in SA patients.
Further, with respect to copy number changes in rela-
tion to histological types, chromosomal gains of 8q and
17q and losses of 3p have been described to be associated
with intestinal type gastric cancers [33]. On the other
hand, gains of 8q and 17q have been reported to be
altered predominantly in diffuse type gastric cancers [38].
In the present study gains on chromosomes 8q and 17q
and losses on 3p were common to both intestinal and dif-
fuse type gastric cancers. In addition, these aberrations
also were common in tumors from both UK and SA
patients. Gains on chromosomes 13q and 19q have been
found more frequently in diffuse type gastric cancers
[33,36,38]. Again, in the present study, gains of these
chromosomes were observed equally in intestinal and dif-
fuse type gastric cancers. Gain of 19q was frequently
observed in tumors from both geographical origins.
Although gain of 13q was observed less frequently in
tumors from SA patients compared to tumors from UK
patients, still around 20-25% of the tumors of native SA
patients show a gain of chromosome 13q, making it unli-
kely that tumor type has influenced cluster membership.
A limitation of the present study is the fact that native
SA gastric cancer patients were significantly younger
compared to Caucasian SA and UK gastric cancer
patients. We previously showed that gastric cancers of
young and elderly patients have different patterns of
chromosomal aberrations [12]. We cannot rule out that
also in these series, age might contribute to differences
in DNA copy number profiles, however cluster analysis
showed that gastric cancers from native SA patients
were more similar to cancers from Caucasian SA
patients, who have similar age as UK patients, indicating
that cluster membership is independent of age in this
respect. Overall, most differences were observed
between UK and native SA tumors.
We realize that the present study is based on a hetero-
geneous group of gastric cancer patients, with different
genetic background and different environmental factors,
including H. pylori, diet and socioeconomic status,
influencing gastric cancer risk. Statements on genotype
influencing gastric cancer are very difficult to make
since the degree of heterogeneity within each different
patient group, i.e. UK, native SA and Caucasian SA, is
unknown.
The patterns of genomic alterations in gastric cancers
from UK and SA patients could gain clinical relevance
in the future. In addition to surgery, gastric cancer treat-
ment increasingly includes (neo)adjuvant chemotherapy
and/or radiotherapy, however still without patients
being stratified based on biological characteristics of
their tumors. Clinical trials are underway in which also
the value of genetic markers for predicting response to
therapy are studied. In the end, stratification for therapy
may include genomic alterations observed in tumors of
patients from different geographical origin.
Conclusions
We showed that gastric cancers of UK and SA patients
are different in their patterns of genomic instability.
Gastric cancers from SA patients show higher frequen-
cies of microsatellite instability and different patterns of
chromosomal aberrations compared to gastric cancers
from UK patients. These results may suggest different
molecular pathways of gastric carcinogenesis, consistent
with the African enigma hypothesis. Further studies are
needed to explore the link between H. pylori and other
environmental factors, as well as host factors, such as
polymorphisms influencing gastric cancer susceptibility,
in relation to the patterns of genomic instability in gas-
tric cancers from these different geographic areas.
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